Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05796973 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Measuring Oncological Value of Exercise and Statin

Study acronym: MOVES
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2025 to Dec 31, 2027
    • Eligibility criteria shortened, about 16 words
    • Study description shortened, about 30 words
    v4
  2. Eligibility criteria expanded, about 58 words
    • Study description expanded, about 51 words
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 17, 2023 to Mar 31, 2023
    • Site details revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Tampere University Hospital
57 trials monitored
See 2 trials at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Prostate Cancer
2,546 trials monitored
See 172 trials at risk
Ovarian Cancer
1,336 trials monitored
See 90 trials at risk
and 1 more disease
The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to unsupervised exercise. In addition, the investigators are investigating whether the use of atorvastatin combined with guided group exercise training would further improve the response to cancer treatment.
Trial Details
NCT Number NCT05796973
Lead Sponsor Tampere University Hospital
Collaborators: Tampere University, Aalto University, University of Helsinki, University of Turku
Conditions
(from sponsor)		 Prostate Cancer, Breast Cancer, Kidney Cancer, Ovarian Cancer, Metastatic Breast Cancer, Metastatic Kidney Cancer, Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer +4 more
Related terms Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms
Enrollment 240 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov